Traws Pharma, Inc. (TRAW) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
| Previous Close | 0.83 |
| Open | 0.82 |
| Day High | 0.87 |
| Day Low | 0.82 |
| 52-Week High | 3.27 |
| 52-Week Low | 0.64 |
| Volume | 125,512 |
| Average Volume | 2.32M |
| Market Cap | 7.56M |
| PE | -0.67 |
| EPS | -1.24 |
| Moving Average 50 Days | 1.36 |
| Moving Average 200 Days | 1.85 |
| Change | -0.01 |
Traws Pharma Completes Analysis of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients and Provides Updates for Additional Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza
GlobeNewswire Inc.
Feb 19, 2026 12:30 PM GMT
Completed clinical results with ratutrelvir confirm a differentiated profile versus PAXLOVID® with fewer adverse events and no viral rebounds with equivalent time to sustained symptom resolution; results were recapitulated in PAXLOVID®-ineligible pat
Traws Pharma Completes Enrollment of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients; Announces Plans for Added Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza
GlobeNewswire Inc.
Jan 26, 2026 1:30 PM GMT
Ongoing clinical results with ratutrelvir confirm a differentiated profile versus PAXLOVID® with fewer adverse events, no viral rebounds to date and faster time to sustained symptom resolution; results recapitulated in PAXLOVID®-ineligible patients,
Traws Pharma Files Tivoxavir Marboxil Investigational New Drug (IND) Application for Influenza Therapy, and Provides Updated Results from the Ongoing Clinical Study of Ratutrelvir in PAXLOVID®-Eligible and Ineligible COVID-19 Patients
GlobeNewswire Inc.
Jan 13, 2026 12:00 PM GMT
IND filing of tivoxavir marboxil represents final step for formal consideration by the Center for the Biomedical Advanced Research and Development Authority (BARDA) for inclusion in strategic stockpile Updated clinical results with ratutrelvir confir